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Background: Cerebral Amyloid Angiopathy (CAA) is present in most cases
of Alzheimer’s disease (AD), and it is characterized by the deposition of
beta-amyloid (A) in cerebral cortical and meningeal blood vessels (Kawai M.
et al., 1993), inducing degeneration of vascular cells. Semicarbazide-sensitive
amine oxidase (SSAO) [E.C. 1.4.3.6] is present in vascular cells and in plasma.
It metabolizes primary amines (Lyles GA., 1996) generating hydrogen perox-
ide (H2O2), ammonia (NH3) and the corresponding aldehyde, that contribute to
the oxidative stress, advanced glycation end-product generation (Gubisne-
Haberle D. et al., 2004), and beta amyloid aggregation (Chen K. et al., 2006).
Furthermore in endothelial cells, SSAO is induced under inflammatory con-
ditions (Smith D.J. et. al., 1998). We have reported that SSAO is overex-
pressed in cerebrovascular tissue of patients with CAA-AD, and that it colo-
calizes with beta-amyloid deposits (Ferrer I. et al., 2002). This over-expression
correlates with high SSAO activity in plasma of severe AD patients (del Mar
Hernandez M. et al., 2005). We have also described that plasma SSAO is able
to induce apoptosis in vascular cells (Hernandez M. et.al., 2006). The aim of
this work is to demonstrate whether A is able to induce SSAO overexpres-
sion in HUVEC cells as vascular cell type. Methods: Because of the SSAO/
VAP-1 expression fenotype is lost in cultured cells, HUVEC (human umbilical
vein endothelial cells) cells, were stably transfected with vector pcDNA 3.1
containing hVAP-1/SSAO. Cells were treated with A 1-40 Dutch type
(mutation E22Q) and/or Methylamine as SSAO substrate. Cell viability,
SSAO activity and its expression were determined using specific antibodies
against SSAO. Results: Herein we report that A 1-40 E22Q induces the
SSAO activity and expression in HUVEC cells. This increasing activity pro-
motes oxidative stress that enhances the toxicity generated by A alone. This
toxicity is reverted by specific SSAO inhibitors, confirming SSAO as the
responsible of such effect. Conclusions: These results allow us to postulate
that deposits of A in cerebrovascular tissue, induce SSAO expression that
may contribute to the vascular damage associated to CAA-AD.
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Background: Alzheimer’s disease (AD) brains are marked by deposition of
amyloid peptides, especially amyloid beta1-42 (A42), within neurons and
amyloid plaques. Causal mechanisms for A42 deposition remain unknown.
Several studies have reported that neurons in post-mortem AD brains are
immunopositive for immunoglobulins (Igs), suggesting that serum Igs gain
access to neurons in AD brains by penetrating the blood-brain barrier. In the
present study, we tested the possibility that binding of Igs to neurons contrib-
utes to neuronal internalization and accumulation of A42 during AD patho-
genesis. Methods: Sera from AD and healthy, non-demented individuals were
screened for neuron-binding autoantibodies by using it as primary antibody on
histological sections of human AD and age-matched control brains and in
western blots of proteins isolated from brain membranes. The effects of human
neuron-binding antibodies on A42 deposition were tested in adult mouse
brain neurons in vitro (using organotypic brain slice cultures) and in vivo
(using direct stereotaxic intracranial injection). Results: Neuron-binding au-
toantibodies were detected in nearly all sera from AD individuals and control
subjects. These antibodies immunolabeled comparable neurons in histological
sections of both human and adult mouse brain. Taking advantage of this
species cross-reactivity, we demonstrate that binding of human autoantibodies
to neurons dramatically enhances the rate and extent of A42 accumulation in
neurons in brain slice cultures as well as in mice receiving stereotaxic intra-
cranial injections of human antibodies and A42. Furthermore, individual sera
that most intensely immunolabeled neurons in sections of human brain tissue
and brain membrane proteins in western blots were also found to be the most
effective at inducing internalization of soluble exogenous A42 in mouse
neurons. Conclusions: The high prevalence of neuron-binding autoantibodies
in human serum leads us to propose that these autoantibodies may be a risk
factor for AD as well as other neurodegenerative diseases that involve BBB
compromise. Moreover, influx of blood-borne, neuron-binding autoantibodies
and soluble A42 into the brain may contribute to AD by exacerbating the
intraneuronal accumulation of A42 and amyloid deposition in the brain
tissue.
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Background: Dense-core amyloid- (A) plaques and congophilic amyloid
angiopathy are pathological hallmarks of Alzheimer’s disease (AD). However,
it is not yet clear how these deposits initially aggregate, i.e. whether aggrega-
tion is spontaneous or is mediated by specific interactions of A with other
brain proteins. We recently showed that dense-core plaques in Tg2576 and
PSAPP mouse models and in Flemish APP A692G AD patients are centered
on vessel walls and this is also supported by similar recent observations on AD
and Down’s syndrome patients. Even more importantly, considerable micro-
vascular damage and blood-brain barrier abnormalities were also identified in
both amyloid-associated and non-amyloidogenic vessels in the AD mouse
models and in AD patients. Objectives: To identify seeding factors responsible
for the vascular entrapment of A and to elucidate changes occurring in blood
vessels even prior to amyloid deposition by a mixed transcriptomic and
proteomic approach. Methods: Tg2576, TgN, BRI-A42, and BRI-A40 AD
mouse models and littermate controls of different ages are utilized to isolate
vascular early dense-core plaques and non-amyloidotic vessels by laser mi-
crodissection (PALM MicroBeam, Zeiss) for transcriptional profiling by Agi-
lent microarrays. Frontal neocortical and entire hippocampal tissue of Tg2576
mice and littermate controls are also laser-microdissected as these are the first
regions where A is being deposited in these mice. In addition, 2D-DIGE and
MALDI-TOF MS/MS analyses will also be performed on this tissue. Results:
For optimal transcript preservation, a short twenty-minutes staining protocol
has been optimized to visualize early A deposits and/or vessels in brains of
transgenic mice and littermate controls. Frozen brain sections were fixed with
ice-cold 70% ethanol and fluorescently stained with Thioflavin-S and collagen
IV. High-quality total RNA suitable for microarray studies as measured with
Experion HighSens chip was extracted from the laser-microdissected tissue.
Currently, microarray analyses are being done to elucidate changes in the gene
expression profile. Conclusions: Our data suggest that extraction of high-
quality RNA from small amounts of laser-microdissected tissue is possible.
The strategy discussed here will be important to elucidate the molecular
mechanisms of plaque formation and the vascular changes that occur in blood
vessels prior to A deposition in Alzheimer Disease.
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Background: Diabetes mellitus (DM), both insulin-dependent and non-
insulin dependent has a proven negative influence on the level of cognitive
functions. Apart from hypertension, ischaemic heart disease, dyslipidae-
mia, DM is considered one of the primary risk factors for vascular demen-
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